Explore a selection of our essential drug information below, or:
Identification
- Summary
VidPrevtyn Beta is a recombinant, adjuvanted DNA vaccine given as a booster dose to prevent COVID-19.
- Generic Name
- VidPrevtyn Beta
- DrugBank Accession Number
- DB16427
- Background
VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur.3 It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda - combined with GSK's AS03 adjuvant.1,4
In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.3
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- COVID-19 Vaccine (recombinant, adjuvanted)
- SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
- External IDs
- SP 0253
- SP-0253
- SP0253
Pharmacology
- Indication
VidPrevtyn Beta is indicated as a booster dose to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Coronavirus disease 2019 (covid‑19) •••••••••••• ••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Compared to tozinameran, VidPrevtyn Beta demonstrated superiority in geometric mean titers (GMT) against Omicron BA.1 and non-inferiority of seroresponse rate against Omicron BA.1 and D614G strains, defined as a 4-fold or greater rise in serum neutralisation titre 28 days post- booster dose relative to pre-booster dose.4
- Mechanism of action
The antigenic component of VidPrevtyn Beta is a soluble trimeric SARS-CoV-2 recombinant spike protein (B.1.351 strain) stabilized in its prefusion conformation and deleted of its transmembrane and intracellular domains.4,5 It is combined with an adjuvant, AS03, that serves to enhance the immune response.4,5 Administered intramuscularly, VidPrevtyn Beta elicits an active immune response that provides protection against COVID-19 caused by SARS-CoV-2.4
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Garcon N, Vaughn DW, Didierlaurent AM: Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. [Article]
- Sanofi: Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly [Link]
- Sanofi Press Release: Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission [Link]
- EMA Summary of Product Characteristics: VidPrevtyn Beta (COVID-19 vaccine, recombinant, adjuvanted) for intramuscular injection [Link]
- EMA Public Assessment Report: VidPrevtyn Beta [Link]
- External Links
- Wikipedia
- COVID-19_vaccine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at January 13, 2021 20:11 / Updated at January 20, 2024 14:03